Here are the 10-K annual reports from Pyxis Oncology, Inc. (PYXS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PYXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PYXS filings page.
Pyxis Oncology is a clinical-stage cancer company focused on its lead antibody-drug conjugate MICVO for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). MICVO targets the EDB+FN splice variant in the tumor microenvironment to deliver an auristatin payload via a three-pronged mechanism of direct killing, bystander effect and immune activation.
Phase 1 monotherapy data in heavily pretreated 2L+ R/M HNSCC at 5.4 mg/kg every three weeks showed a confirmed objective response rate of 46% and disease control in 92% of evaluable patients, with manageable but notable Grade ≥3 treatment-related adverse events, especially in higher body-weight patients. Pyxis is implementing dose caps and adjusted ideal body weight dosing to improve tolerability.
MICVO has Fast Track designation in 2L+ R/M HNSCC, and the company has obtained FDA feedback on a planned pivotal monotherapy trial. A Phase 1/2 combination study with pembrolizumab in 1L/2L+ R/M HNSCC reported a 71% confirmed response rate and 100% disease control in early data, with no Grade 3/4 ADC payload toxicities. Updated monotherapy data are expected mid-2026 and additional combination data in the second half of 2026, while several earlier programs are paused and available for partnering.